10 mai 2024 – Swissmedic informs that the indication and possible use of tolperisone-containing medicinal products has been restricted to the treatment of spasticity associated with cerebrospinal lesions in adults. Tolperisone is no longer authorised for the treatment of muscle spasms in painful diseases of the skeletal muscles.

For more information, see here